Nonetheless, hyperprolactinemia-associated alterations would considerably limit the potential for long-term clinical use in women with pre-existing menstrual irregularities, men with sexual dysfunction, women who are trying to conceive, or persons with PRL-related tumours (breast cancer and pituitary tumours) [37]. This evidence concerns the gene PRL and breast cancer.